Claude Nicaise - 16 Mar 2023 Form 4 Insider Report for Chemomab Therapeutics Ltd. (CMMB)

Role
Director
Signature
/s/ Matthew Rudolph, Esq., Attorney-in-Fact for Claude Nicaise
Issuer symbol
CMMB
Transactions as of
16 Mar 2023
Net transactions value
$0
Form type
4
Filing time
23 Mar 2023, 07:36:58 UTC
Previous filing
08 Mar 2023
Next filing
26 Jun 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CMMB Option to Purchase American Depositary Shares Award $0 +6,857 $0.000000 6,857 16 Mar 2023 American Depositary Shares 6,857 $1.62 Direct F1, F2
transaction CMMB Option to Purchase American Depositary Shares Award $0 +6,820 $0.000000 6,820 16 Mar 2023 American Depositary Shares 6,820 $3.53 Direct F2, F3, F4
transaction CMMB Option to Purchase American Depositary Shares Award $0 +11,884 $0.000000 11,884 16 Mar 2023 American Depositary Shares 11,884 $27.26 Direct F2, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.
F2 Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
F3 No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
F4 These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors.
F5 These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.